Difference between revisions of "Enasidenib (Idhifa)"
Jump to navigation
Jump to search
| Line 9: | Line 9: | ||
== Patient Drug Information== | == Patient Drug Information== | ||
| − | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf Enasidenib (Idhifa) Package Insert] | + | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf Enasidenib (Idhifa) Package Insert] |
==Also known as== | ==Also known as== | ||
Revision as of 10:53, 4 April 2021
Mechanism of action
From the NCI Drug Dictionary: An orally available inhibitor of isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits IDH2 in the mitochondria, which inhibits the formation of 2-hydroxyglutarate (2HG).[1]
Diseases for which it is used
History of changes in FDA indication
- 8/1/2017: Granted FDA regular approval for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.
Patient Drug Information
Also known as
- Code names: AG-221, CC-90007
- Generic name: enasidenib mesylate
- Brand name: Idhifa